When pathological angiogenesis is reconceptualized as a problem of dysregulated EndoMT – and not merely an issue of over-active pro-angiogenic (e.g., VEGF) signaling – it becomes clearer why anti-VEGF therapy [which has been a standard of care in cancer treatment for the last two decades (Welti et al., 2013)] largely fails to provide long-term control of tumor angiogenesis and cancer progression (Ferrara, 2010). Here, VEGFA is linked to neoplasm.